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Abstract: Glulisine is a US Food and Drug Administration (FDA) approved insulin analogue, used for
controlling hyperglycaemia in patients with diabetes mellitus (DM). It is fast acting which better
approximates physiological insulin secretion, improving patient outcome. Crystallisation of Glulisine
was analysed by its crystallisation phase diagram and nucleation-inducing materials. Both the hanging
drop vapour diffusion and microbatch-under-oil methods were used and compared. We have shown
that the same protein can have different solubility behaviours depending on the nature of the salt in
the precipitating agent. In the case of Glulisine with magnesium formate, lowering the precipitant
concentration drove the system further into supersaturation resulting in the formation of crystals
and precipitation. This was the opposite effect to the usual scenario where raising the precipitant
concentration leads to supersaturation. Glulisine with sodium potassium tartrate tetrahydrate (NaKT)
followed the expected trend of forming crystals or precipitate at higher concentrations and clear
drops at lower concentrations of the precipitant. The outcomes of crystallisation using the different
crystallisation methods is also described. Glulisine was successfully crystallised and the crystals
diffracted up to a resolution limit of 1.4 Å.
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1. Introduction
High-resolution X-ray diffraction patterns require high-quality crystals and obtaining such crystals
is often the bottleneck of the structural determination process [1]. Advances in automation and
high throughput screening can increase the number of hits obtained but it does not address the
core problem of reliance on trial and error [2]. For a more systematic approach to crystallisation,
we must consider the principles underlining crystal formation. As the aqueous solution containing the
protein reaches supersaturation, protein molecules will come out of the solution and under specific
conditions form crystals. A variety of parameters such as protein concentration, crystallising agent or
precipitant and additives can be adjusted to encourage the formation of crystals. A phase diagram can
be experimentally generated and quantify the effect of such modifications. The phase diagram is a 2D
representation of the distinct phases that occur and coexist at equilibrium [3].
1.1. The Application of the Phase Diagram and Nucleants
The zones of undersaturation and supersaturation are the main areas of the phase diagram,
which is separated by the solubility curve. The supersaturation zone can be further divided into
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metastable, nucleation and precipitation zones depending on the levels of supersaturation. No crystals
will form at conditions where the solution is undersaturated. By increasing the concentration of protein
or another adjustable parameter, we can push the system towards crystallisation. The metastable
zone is where crystals can grow but no nucleation will take place on the timescale of the experiment.
The nucleation zone, as the name suggests is where nuclei form. Crystals can only grow from a
nucleus so it is important to encourage nucleation but at the same time prevent excessive nucleation
where a shower of microcrystals will form as a result [4]. The metastable and nucleation zone is
separated by the supersolubility curve. For practical purposes, it is sufficient to experimentally
determine the supersolubility curve as determining the solubility curve requires larger amounts of
materials and increases the length of the experimental time by weeks or even months [5,6]. A diagram
containing only the supersolubility curve is called a working phase diagram [6,7]. At even higher
conditions, precipitates will form due to high supersaturation [6]. The trajectory to supersaturation of
a crystallisation drop can have drastic effects on the outcome. It is advisable, therefore, to carry out
crystallisation experiments with different methods.
Once metastable conditions have been identified with the aid of the phase diagram, the nucleation
zone can be completely bypassed. If left undisturbed, no nucleus will form at metastable conditions,
and the crystallisation drop will remain clear indefinitely. However, certain materials known as
nucleants have the property to induce nucleation at metastable conditions as they provide more
energetically favourable conditions for heterogeneous nucleation [8]. Porous materials have generated
much interest as potential nucleants [9]. The cavities on porous materials have the ability to attract
and entrap protein molecules [10]. A crystal can start growing in the pore after a critical nucleus is
formed [11]. A silicate bioglass material (Naomi’s nucleant) has a highly porous surface with cavities
of similar sizes to typical proteins (2–10 nm) [12]. The number of proteins crystallised using Naomi’s
nucleant is continuously rising [1,13] and to date, it has assisted in the crystallisation of over 20 proteins.
Another nucleating material currently being investigated is nanoporous gold foil containing 5–10 nm
pores [14].
1.2. Glulisine
Glulisine/Apidra is a Food and Drug Administration (FDA) approved fast-acting insulin analogue,
used for controlling hyperglycaemia in patients with diabetes mellitus. The aim of insulin therapy
is to mimic physiological insulin secretion; this is better achieved by the use of modified insulin
analogues [15]. The combination of fast and slow-acting insulin analogues can provide effective
coverage to prevent the glucose spike immediately after meals and maintains the glucose concentration
at a homeostatic level. In Glulisine, the B chain residues 3 and 29 were changed from asparagine to
lysine and lysine to glutamic acid, respectively [16]. When administered, Glulisine is absorbed faster
into the bloodstream than regular human insulin and better approximates microvascular flow and
endothelial function [17,18]. To date, there is no published Glulisine structure other than the Protein
Data Bank (PDB) deposition at 1.26 Å (PDB ID 6GV0) [19].
The aim of this work was to obtain diffracting crystals and to conduct a systematic study on the
crystallisation of Glulisine by applying phase diagrams and controlling nucleation.
2. Materials and Methods
2.1. Protein and Precipitants
Pharmaceutical grade Glulisine/Apidra (Sanofi S.A., Paris, France) (5F337A) was obtained in
solution at 3.49 mg/mL. Initial crystallisation screening trials were set up using the Index screen
(Hampton Research, Aliso Viejo, CA, USA). Optimisation was performed with two promising screening
conditions, one consisting of 0.1 M 2,2-Bis(hydroxymethyl)-2,2′,2”-nitrilotriethanol (BIS-TRIS) pH
5.5–6.2 and 0.1–0.9 M magnesium formate and the other of 0.1–0.8 M sodium potassium tartrate
tetrahydrate, 0.1 M Tris pH 8.5 and 0.5% w/v polyethylene glycol monomethyl ether 5000 (Sigma Aldrich,
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St. Louis, MO, USA). The crystallisation solutions containing magnesium formate at pH 5.5 or sodium
potassium tartrate tetrahydrate (NaKT) at pH 8.5 were used in all the experiments following screening.
The concentration of protein was changed by adjusting the ratio of Glulisine and precipitant in the
crystallisation drop.
All experiments were set up in duplicate drops. All incubations were carried out at 20 ◦C and
observed daily for at least four weeks. Crystallisation drops were observed with a Leica M165 C
microscope and images were captured with the Leica DFC295 camera and processed with Leica
Application Suite software.
2.2. Crystallisation Methods
Hanging drop vapour diffusion experiments were set up using the EasyXtal plates with X-Seal
crystallisation supports (Qiagen, Hilden, Germany). The reservoir contained 300 µL of the precipitant
solution and 1 µL each of the protein and precipitant solution were mixed on the X-Seal supports.
The X-Seal supports were then inverted and screwed above the precipitant reservoir creating an airtight
seal. By changing the protein:precipitant ratio (1:2, 1:1.5, 1:1, 1.5:1 and 2:1), 1.16, 1.40, 1.75, 2.09 and
2.33 mg/mL working concentrations of Glulisine was achieved.
Microbatch experiments [20] were carried out in Nunc HLA Terasaki 72 well plates (Douglas Instruments,
East Garston, UK). The plates were cleaned with compressed air and then filled with 100% paraffin oil.
Protein and precipitant drops were dispensed under the paraffin oil at the ratios above.
2.3. Nucleants
The following nucleating agents were added to the crystallisation drop to encourage nucleation
and the subsequent growth of crystals. Naomi’s nucleant was available in our laboratory. One grain
was inserted into each crystallisation drop with fine-tip forceps. Nanoporous gold (provided by Prof. J.
Erlerbacher, Johns Hopkins University, Baltimore, MD, USA) was also inserted one piece per drop.
2.4. Crystal Harvesting and Data Collection
Appropriately sized nylon loops (Hampton Research, Aliso Viejo, CA, USA) were used to harvest
crystals from the drop. A cryoprotectant composed of 20% glycerol and 80% precipitant was used.
Crystals were then flash-frozen and stored in liquid nitrogen. X-ray diffraction was performed remotely
at Imperial College using the I04-1 beamline at the Diamond Light Source, Oxford.
3. Results
3.1. Glulisine and Magnesium Formate
Working phase diagrams for Glulisine with magnesium formate as the precipitant were constructed
for both the vapour diffusion and microbatch methods (Figure 1) by varying the concentration
of Glulisine (1.16–2.33 mg/mL) and magnesium formate in the precipitant solution (0.05–0.9 M).
The solubility of magnesium formate is 1 M in water, hence no trials were set up beyond the
concentration of 0.9 M.
At 1.75 mg/mL Glulisine crystal formation was observed within 16 hours at 0.2 M magnesium
formate concentrations in both vapour diffusion and microbatch. At 0.3 M and 0.4 M magnesium
formate crystals formed within seven days in microbatch and over two weeks in vapour diffusion.
At concentrations below 0.2 M magnesium formate, Glulisine precipitated out of solution while at
concentrations above 0.6 M magnesium formate all drops remained clear for four weeks. Trials with
0.8 and 0.9 M magnesium formate remained clear for over 10 weeks.
At 2.33 mg/mL Glulisine, microcrystals and precipitate formed within 24 hours at 0.1 and 0.2 M
magnesium formate concentrations in both vapour diffusion and microbatch. At 2.33 mg/mL Glulisine
and magnesium formate concentrations above 0.3 M, crystals formed within two weeks in vapour
diffusion and within seven days in microbatch.
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Figure 1. Working phase diagrams for Glulisine crystallisation with magnesium formate as 
precipitant. (A) vapour diffusion, (B) microbatch. 
Having identified metastable regions, Naomi’s nucleant and nanoporous gold were inserted into 
the crystallisation drops at conditions just below the supersolubility curve. At 1.16 mg/mL Glulisine 
and 0.3 M magnesium formate, Naomi’s nucleant produced crystals (200 × 100 µm) on day seven in 
vapour diffusion (Figure 2A). The drops at 1.16 mg/mL Glulisine and 0.2 M magnesium formate 
(these were supersaturated conditions where crystals form spontaneously) produced crystals (100 × 
100 µm) without the addition of nucleants on day one in vapour diffusion, however, they were 
stacked and not single (Figure 2C) whilst the crystals obtained with Naomi’s nucleant were single 
and diffracted to 1.4 Å (Figure 2B). Naomi’s nucleant did not produce crystals in microbatch under 
the same conditions and nanoporous gold was ineffective in both methods. Control drops at 1.16 
mg/mL Glulisine and 0.3 M magnesium formate without the addition of nucleants remained clear 
over the four-week incubation period. 
Figure 1. Working phase diagrams for Glulisine crystallisation with magnesium formate as precipitant.
(A) vapour diffusion, (B) microbatch.
Having identified metastable regions, Naomi’s nucleant and nanoporous gold were inserted into the
crystallisation drops at conditions just below the supersolubility curve. At 1.16 mg/mL Glulisine and 0.3 M
magnesium formate, Naomi’s nucleant produced crystals (200× 100 µm) on day seven in vapour diffusion
(Figure 2A). The d ops at 1.16 mg/mL Glulisin and 0.2 M agnesium formate (these were supersaturated
conditions where crystals form spontaneously) produced crystals (100 × 100 µm) without the addition of
nucleants on day one in vapour diffusion, however, they were stacked and not single (Figure 2C) whilst
the crystals obtained with Naomi’s nucleant were single and diffracted to 1.4 Å (Figure 2B). Naomi’s
nucleant did not produce crystals in microbatch under the same c ditions and nanoporous gold was
ineffective in both methods. Control drops at 1.16 mg/mL Glulisine and 0.3 M magnesium formate
without the addition of nucleants remained clear over the four-week incubation period.Crystals 2019, 9, x FOR PEER REVIEW 5 of 9 
 
 
Figure 2. (A) Glulisine crystals produced in metastable conditions at 1.16 mg/mL Glulisine and 0.3 M 
magnesium formate with Naomi’s nucleant. (B) Crystals obtained at supersaturated conditions at 1.16 
mg/mL Glulisine and 0.2 M magnesium formate with no nucleants. (C) Diffraction of up to a 
resolution limit of 1.4 Å of the crystals in (A). 
3.2. Glulisine and Sodium Potassium Tartrate Tetrahydrate (NaKT) 
A working phase diagram was generated by varying the concentration of Glulisine (1.16–2.33 
mg/mL) and NaKT (0.1–0.8 M) in the precipitant solution (Figure 3). Microbatch was ineffective at 
crystallising Glulisine with NaKT as precipitant. At concentrations below 0.2 M NaKT, drops 
remained clear for four weeks for all Glulisine concentrations. At NaKT concentrations above 0.4 M, 
precipitates and microcrystals formed overnight, and larger crystals (100 × 100 µm) were produced 
three weeks after set-up. Some crystals took over 40 days to form. Crystals grown with 0.4 M NaKT 
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were not large enough for diffraction. 
Having identified metastable regions, Naomi’s nucleant and nanoporous gold were inserted into 
the crystallisation drops at 0.2 M NaKT but no crystals were obtained under these conditions. 
 
Figure 2. (A) Glulisine crystals produced in meta t le conditions at 1.16 mg/mL Glulisine and 0.3 M
magnesiu formate with Naomi’s nuclea t. (B) Cry tals obt ined at supersaturated conditions at
1.16 mg/mL Glulisine and 0.2 M magnesium formate with no nucleants. (C) Diffraction of up to a
resolution limit of 1.4 Å of the crystals in (A).
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3.2. Glulisine and Sodium Potassium Tartrate Tetrahydrate (NaKT)
A working phase diagram was generated by varying the concentration of Glulisine
(1.16–2.33 mg/mL) and NaKT (0.1–0.8 M) in the precipitant solution (Figure 3). Microbatch was
ineffective at crystallising Glulisine with NaKT as precipitant. At concentrations below 0.2 M NaKT,
drops remained clear for four weeks for all Glulisine concentrations. At NaKT concentrations above
0.4 M, precipitates and microcrystals formed overnight, and larger crystals (100 × 100 µm) were
produced three weeks after set-up. Some crystals took over 40 days to form. Crystals grown with 0.4
M NaKT and 1.75 mg/mL Glulisine in vapour diffusion were large and single (100 × 100 µm) compared
to the crystals grown in the microbatch. They were X-rayed and the diffraction at 2.3 Å was inferior to
Glulisine crystals grown in magnesium formate. The crystals obtained at 0.4 M NaKT in microbatch
were not large enough for diffraction.Crystals 2019, 9, x FOR PEER REVIEW 6 of 9 
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Figure 3. Working phase diagram for Glulisine crystallisation with sodium potassium tartrate tetrahydrate
(NaKT) as precipitant using vapour diffusion.
Having identified metastable regions, Naomi’s nucleant and nanoporous gold were inserted into
the crystallisation drops at 0.2 M NaKT but no crystals were obtained under these conditions.
4. Discussion
Macromolecular crystallisation still presents a major challenge for structural determination
proj cts. The u predictability and almost randomness of crystal formation have p evented the success
of many projects [1]. Over the years, a substantial amount of research has been directed to better
understand the crystallisatio process and to encourage the formation of crystals.
4.1. The Solubility of Glulisine
The phase diagram provides a systematic approach to optimise promising results from the screening
rocess. In the case of Glulisine with magnesium formate, lowering the precipitant concentration
drove the system further into supersaturation resulting in the formation of crystals and precipitation.
This was the opposite effect to the us al scenario where raising the precipitant concentration leads
to supersaturation. The solubility of a protein in solution is governed by two principles: “salting in”
and “salting out” [21]. The ability of cations and anio s to salt in or salt out protei s is organised as
the Hofmeister series where ions are ranked by their ability to solubilise and precipitate proteins [22].
As salt io s are added i to the solution at low concentrations, the electrostatic energy between protein
molecules is reduced, stabilising and increasing the solubility of the protein—this is salting in. As the
concentration of the salt in solution rises, the excess ions compete with the protein for i teractions with
water molecules, effectively strengthening the hydrophobic interaction between proteins molecules.
Without a layer of water molecules surrounding each protein molecule, proteins will start to aggregate
and eventually precipitate o t of the solution—this is salting out [21].
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It is likely that magnesium formate is necessary for Glulisine to solubilise. The magnesium ion in
solution has a high kosmotropic effect as the charge density on the small ion is high. This allows it to
form interactions with the surrounding water molecules [23]. The bonding between a kosmotrope and
water is greater than the bonding between water molecules themselves, therefore, the water–water
hydrogen bonding is disrupted. The density of water is reduced as hydrogen bonds are broken allowing
for more protein molecules to be dissolved. Without magnesium, the water starts to reorganise and
Glulisine starts to aggregate and precipitate out of solution. As the solubility of magnesium formate in
water is relatively low at 1 M [24], it might not be possible for the magnesium formate precipitant to
cause supersaturation thus the crystallisation drop remains clear. Crystals are formed by reducing the
solubility of the protein rather than the conventional process of increasing saturation of the drop.
The crystallisation of Glulisine with NaKT followed the usual trend where increased salt
concentration resulted in the formation of crystals and amorphous precipitate. The charge density
of sodium and potassium ions are lower compared to that of magnesium ions and do not affect the
structuring of the water molecules as much Reference [25]. Thus, the solubility of Glulisine was less
affected by the concentration of NaKT. It was interesting to see contrasting trends in the same protein.
Moreover, crystals formed much more slowly with NaKT as precipitant, often taking weeks rather
than days to form (four weeks after setting up the trials with NaKT at 3.49 mg/mL of the protein),
whereas magnesium formate produced crystals in as little as 16 hours. It was interesting to note that
despite the slow formation and growth of crystals in NaKT, their diffraction quality was much worse
than crystals grown with magnesium formate (2.3 Å compared to 1.4 Å). These results emphasise the
importance of the role of the precipitant used in crystallisation.
4.2. Experimental and Technical Evaluations
Vapour diffusion and microbatch follow different kinetics which can lead to different outcomes [26].
In batch experiments, the drop reaches instant supersaturation when the protein and precipitant are
mixed, whereas in vapour diffusion experiments, the drop is undersaturated and the precipitant
reservoir will slowly draw water out of the crystallisation drop and increase its saturation. As the
conditions in vapour diffusion experiments change over time, there is a self-screening process as
the drop saturation increases, whereas there is very little change in drop conditions under paraffin
oil [26]. However, in the case of Glulisine with magnesium formate, crystals were produced in many
more conditions in microbatch than in vapour diffusion, implying that Glulisine preferred to reach
instant supersaturation. In addition, crystals in microbatch appeared faster than in vapour diffusion
(seven days compared to two weeks). In contrast, when using NaKT as precipitant, vapour diffusion
produced crystals under more conditions compared to microbatch. This highlighted the importance of
the precipitant and the crystallisation method used.
The marketed formulation of Apidra consists of a mixture of Glulisine oligomers, not purely
hexamers. The proportion of Glulisine monomers increases with dilution of Apidra. At 3.49 mg/mL,
the Apidra formulation contains 25% Glulisine monomers; this increases to 37% at 1.74 mg/mL [27].
Large complexes of Glulisine are present at higher concentrations and when diluted, they readily
dissociate into monomers which attributes to the rapid activity of Glulisine in vivo [17]. Naomi’s
nucleant successfully produced diffracting crystals at metastable conditions of 0.3 M magnesium
formate and 1.16 mg/mL Glulisine. However, under identical conditions, the nanoporous gold did
not produce crystals. This may be attributed to the difference in pore size between the two materials.
Nanoporous gold contains 5 to 10 nm sized pores, whereas Naomi’s nucleant contains pores ranging
between 2 to 10 nm. Since it is the ability of the cavities to attract and entrap protein molecules that
lead to crystal formation it may be that the pores of the gold foil are too large for Glulisine, which has
varying radii molecules due a mixture of monomers and other oligomers.
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4.3. Conclusions
The reported study presented the crystallisation of the rapid-acting insulin analogue Glulisine
assisted by phase diagrams and nucleants. We have shown that the same protein can have different
solubility behaviours depending on the nature of the salt in the precipitating agent. Glulisine with
magnesium formate produced crystals faster at lower concentrations but with NaKT the opposite was
observed. Interestingly, the microbatch also produced crystals faster (16 h) than in vapour diffusion
trials (48 h) with magnesium formate. Glulisine with NaKT followed the expected trends i.e., forming
crystals or precipitate at higher concentration and clear drops at lower concentrations of the precipitant.
Glulisine was successfully crystallised and the crystals diffracted up to a resolution limit of 1.4 Å.
As Glulisine is a very interesting protein regarding its opposite solubility behaviour in the presence
of different salts, it is an excellent candidate for further systematic studies to understand crystallisation.
Glulisine will be a unique model protein as it is also of medical interest, unlike current model proteins
such as lysozyme, thaumatin etc. which are very commonly studied.
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